QNCX Long Call Strategy

QNCX (Quince Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

QNCX (Quince Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $9.5M, a beta of 1.40 versus the broader market, a 52-week range of 15.1-910, average daily share volume of 56K, a public-listing history dating back to 2019, approximately 38 full-time employees. These structural characteristics shape how QNCX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.40 indicates QNCX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on QNCX?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

QNCX snapshot

As of August 14, 2026, spot at $31.50, ATM IV 377.80%, IV rank 75.90%, expected move 108.31%. The long call on QNCX below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.

Why this long call structure on QNCX specifically: QNCX IV at 377.80% is rich versus its 1-year range, which makes a premium-buying QNCX long call relatively expensive in absolute-cost terms, with a market-implied 1-standard-deviation move of approximately 108.31% (roughly $34.12 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated QNCX expiries trade a higher absolute premium for lower per-day decay. Position sizing on QNCX should anchor to the underlying notional of $31.50 per share and to the trader's directional view on QNCX stock.

QNCX long call setup

The QNCX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With QNCX at $31.50 on that close, the first option leg uses a $31.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed QNCX chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 QNCX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$31.50N/A

QNCX long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

QNCX long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on QNCX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on QNCX

Long calls on QNCX express a bullish thesis with defined risk; traders use them ahead of QNCX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

QNCX thesis for this long call

The market-implied 1-standard-deviation range for QNCX extends from approximately $-2.62 on the downside to $65.62 on the upside. A QNCX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current QNCX IV rank near 75.90% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on QNCX at 377.80%. As a Healthcare name, QNCX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to QNCX-specific events.

QNCX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. QNCX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move QNCX alongside the broader basket even when QNCX-specific fundamentals are unchanged. Long-premium structures like a long call on QNCX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current QNCX chain quotes before placing a trade.

Frequently asked questions

What is a long call on QNCX?
A long call on QNCX is the long call strategy applied to QNCX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With QNCX stock at $31.50 on the most recent close, the strikes shown on this page are snapped to the nearest listed QNCX chain strike and the premiums come straight from that session's bid/ask midpoint.
How are QNCX long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the QNCX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 377.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a QNCX long call?
The breakeven for the QNCX long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The QNCX market-implied 1-standard-deviation expected move in the same options snapshot is approximately 108.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on QNCX?
Long calls on QNCX express a bullish thesis with defined risk; traders use them ahead of QNCX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current QNCX implied volatility affect this long call?
QNCX ATM IV is at 377.80% with IV rank near 75.90%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.

Related QNCX analysis